Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
28.31
-2.94 (-9.41%)
At close: Sep 25, 2026, 4:00 PM EDT
28.42
+0.11 (0.39%)
After-hours: Sep 25, 2026, 7:49 PM EDT
Neurogene Market Cap
Neurogene has a market cap or net worth of $566.52 million as of September 25, 2026. Its market cap has increased by 130.12% in one year.
Market Cap
566.52M
Enterprise Value
349.48M
1-Year Change
130.12%
Ranking
Category
Stock Price
$28.31
ChartMarket Cap Chart
Since December 19, 2023, Neurogene's market cap has increased from $193.64M to $566.52M, an increase of 192.57%. That is a compound annual growth rate of 47.34%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 25, 2026 | 566.52M | 77.54% |
| Dec 31, 2025 | 319.09M | -6.03% |
| Dec 31, 2024 | 339.58M | 36.64% |
| Dec 29, 2023 | 248.52M | 28.34% |
| Dec 19, 2023 | 193.64M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Crescent Biopharma | 598.79M |
| Altimmune | 595.22M |
| CytomX Therapeutics | 588.33M |
| MapLight Therapeutics | 581.32M |
| Phathom Pharmaceuticals | 579.84M |
| Valneva SE | 574.88M |
| Sagimet Biosciences | 574.35M |
| Oculis Holding AG | 572.26M |